SCHEMBL3679142

SCHEMBL3679142

C[C@H](C(N)=O)c1ccc(-c2ccc([C@H](N(C(=O)[C@@H](N)CC(C)(C)F)C3(C#N)CC3)C(F)(F)F)cc2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 5/20 0.43
APP P05067 5/20 0.41
AKR1C3 P42330 4/20 0.40
AKR1C2 P52895 4/20 0.40
CYP2C19 P33261 3/20 0.35
CYP2C9 P11712 2/20 0.35
CYP3A4 P08684 1/20 0.35
PTGS1 P23219 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
PTGS2 P35354 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
FABP2 P12104 1/20 0.35
TSHR P16473 1/20 0.35
AKR1C4 P17516 1/20 0.35
ADRA2B P18089 1/20 0.35
CHRM3 P20309 1/20 0.35
HTR2C P28335 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18203136 1.00 CTSK (0.43) CTSKAPPAKR1C3AKR1C2CYP2C19
SCHEMBL18203128 1.00 CTSK (0.43) CTSKAPPAKR1C3AKR1C2CYP2C19
SCHEMBL3676793 1.00 CTSK (0.43) CTSKAPPAKR1C3AKR1C2CYP2C19
SCHEMBL3679395 1.00 CTSK (0.43) CTSKAPPAKR1C3AKR1C2CYP2C19
SCHEMBL18203132 0.91 CTSK (0.43) CTSKAPPAKR1C3AKR1C2
SCHEMBL3684241 0.90 CTSK (0.44) CTSKAPPAKR1C3AKR1C2CYP2C19
SCHEMBL3685855 0.90 CTSK (0.52) CTSK
SCHEMBL3676440 0.90 CTSK (0.52) CTSK
SCHEMBL3672970 0.90 CTSK (0.52) CTSK
SCHEMBL3676601 0.88 CTSK (0.43) CTSKAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1694647-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK CANADA INC (CA) 2016-11-09 EP claimed
US-7687524-B2 Cathepsin cysteine protease inhibitors MERCK FROSST CANADA & CO. (CA) 2010-03-30 US claimed
US-20070099893-A1 Cathepsin cysteine protease inhibitors MERCK CANADA INC. (CA) 2007-05-03 US claimed
EP-1694647-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK CANADA INC (CA) 2016-11-09 EP disclosed
US-7687524-B2 Cathepsin cysteine protease inhibitors MERCK FROSST CANADA & CO. (CA) 2010-03-30 US disclosed
US-20070099893-A1 Cathepsin cysteine protease inhibitors MERCK CANADA INC. (CA) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099893-A1 Cathepsin cysteine protease inhibitors CTSB, CTSS, CTSZ CTSK 4/4885APP 208/4885AKR1C3 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.